Biotech entity
All 2 tracked stories fall under one category: pharma. Fermi Inc is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 1.8 stories per week across an 8-day span. Their average consequence score of 5 runs below the beat's 6.1 for that window.
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Fermi Inc is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 1.8 stories per week across an 8-day span. Their average consequence score of 5 runs below the beat's 6.1 for that window. They are less corroborated than the beat average, carrying 3 original sources each against 3.4 for the same window. We currently track 2 Biotech stories that mention Ultragenyx Pharmaceutical Inc., published between March 5, 2026 and March 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 115 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ultragenyx Pharmaceutical Inc.. Shared-story counts are live from our verified record — not editorial picks.
Motion to Dismiss Phase
Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
Lead Plaintiff Deadline (Est.)
Typical 60-day window for investors to petition the court to lead the consolidated class action.
Litigation Commencement
Schall Law Firm announces class action lawsuits against both SLNO and RARE.
Investor Alerts Issued
Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector.
Soleno Executive Turnover
Official filing confirms the departure of several directors and officers.
Soleno Financial Results
Soleno files annual results and operational updates.
Ultragenyx Restructuring Disclosure
Company files SEC report detailing costs for exit or disposal activities.
The Schall Law Firm has initiated securities fraud class action lawsuits against biotech players Soleno Therapeutics and Ultragenyx Pharmaceutical. The legal actions follow a series of corporate disclosures in early 2026, inviting impacted investors to lead the litigation efforts.
Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
Ultragenyx Pharmaceutical Inc. is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
